NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ARCT

Arcturus Therapeutics Holdings Inc

Apr 17 • 04:00PM ET

10.53

Dollar change +0.23
Percentage change 2.23	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX PFE NVAX DVAX INO VXRT ALT ADMA ADAP

| Held by: ARKG VTI IWM XBI VXF IWO IBB SCHA VTWO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.00	Insider Own	10.14%	Shs Outstand	27.00M	Perf Week	12.62%
Market Cap	285.57M	Forward P/E	-	EPS next Y	-3.94	Insider Trans	0.00%	Shs Float	24.37M	Perf Month	-21.42%
Income	-80.94M	PEG	-	EPS next Q	-1.18	Inst Own	89.84%	Short Float	19.07%	Perf Quarter	-38.10%
Sales	138.39M	P/S	2.06	EPS this Y	-72.01%	Inst Trans	2.30%	Short Ratio	10.69	Perf Half Y	-49.79%
Book/sh	8.93	P/B	1.18	EPS next Y	23.67%	ROA	-20.93%	Short Interest	4.65M	Perf Year	-65.05%
Cash/sh	10.77	P/C	0.98	EPS next 5Y	38.83%	ROE	-31.16%	52W Range	8.04 - 45.00	Perf YTD	-37.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.84%	ROI	-30.43%	52W High	-76.60%	Beta	2.33
Dividend TTM	-	Quick Ratio	4.67	Sales past 5Y	301.31%	Gross Margin	97.45%	52W Low	30.97%	ATR (14)	0.95
Dividend Ex-Date	-	Current Ratio	4.67	EPS Y/Y TTM	-200.43%	Oper. Margin	-28.27%	RSI (14)	43.15	Volatility	6.96% 8.74%
Employees	176	Debt/Eq	0.12	Sales Y/Y TTM	-13.98%	Profit Margin	-58.49%	Recom	1.00	Target Price	66.33
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	-245.23%	Payout	-	Rel Volume	0.82	Prev Close	10.30
Sales Surprise	-43.01%	EPS Surprise	-102.37%	Sales Q/Q	-25.56%	Earnings	Mar 06 AMC	Avg Volume	434.93K	Price	10.53
SMA20	-0.52%	SMA50	-22.71%	SMA200	-41.97%	Trades		Volume	358,078	Change	2.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-25	Initiated	BTIG Research	Buy	$41
Aug-12-24	Initiated	Leerink Partners	Outperform	$70
Dec-13-23	Initiated	Canaccord Genuity	Buy	$90
Jul-24-23	Initiated	William Blair	Outperform	$71
May-11-23	Upgrade	H.C. Wainwright	Neutral → Buy	$19 → $51
Nov-14-22	Resumed	Wells Fargo	Overweight	$35
Nov-10-22	Downgrade	Robert W. Baird	Neutral → Underperform	$18
Nov-03-22	Upgrade	Citigroup	Neutral → Buy	$22 → $35
Nov-02-22	Upgrade	Barclays	Underweight → Equal Weight	$16 → $25
Aug-10-22	Downgrade	Raymond James	Mkt Perform → Underperform
Jul-19-22	Resumed	Cantor Fitzgerald	Overweight	$86 → $39
May-11-22	Upgrade	Robert W. Baird	Underperform → Neutral	$21 → $18
Apr-21-22	Downgrade	Citigroup	Buy → Neutral	$86 → $29
Jan-31-22	Upgrade	Raymond James	Underperform → Mkt Perform
Aug-12-21	Downgrade	Raymond James	Mkt Perform → Underperform
Aug-11-21	Downgrade	Goldman	Neutral → Sell	$29
Aug-10-21	Downgrade	Robert W. Baird	Neutral → Underperform	$31
Jul-02-21	Initiated	Cantor Fitzgerald	Overweight	$71
Jun-25-21	Resumed	Goldman	Neutral	$29
Jun-21-21	Downgrade	Barclays	Equal Weight → Underweight	$33 → $25

Show Previous Ratings

Apr-11-25 11:49AM	Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate (Zacks)
Apr-10-25 08:00AM	Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 (Business Wire)
Mar-20-25 04:36PM	Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
Mar-07-25 11:16AM	Q4 2024 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -8.89%
02:17AM	Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... (GuruFocus.com)
05:15PM	Loading…
Mar-06-25 05:15PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Arcturus Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress (Business Wire)
Mar-05-25 04:30PM	Arcturus Therapeutics to Present at Leerinks Global Healthcare Conference 2025 (Business Wire)
07:21AM	Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-24-25 04:01PM	Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 (Business Wire) -6.08%
Feb-14-25 08:30AM	European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE, the First Self-amplifying mRNA COVID-19 Vaccine (PR Newswire) +9.99%
Feb-04-25 08:30AM	Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate (Business Wire)
Jan-31-25 03:00AM	Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE, a Self-amplifying mRNA Vaccine Against COVID-19 (Business Wire)
Jan-30-25 04:01PM	Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference (Business Wire)
11:14AM	Loading…
Jan-10-25 11:14AM	Arcturus Therapeutics launches Phase I Avian Influenza trials in US (Clinical Trials Arena) -5.12%
08:00AM	Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial (Business Wire)
Jan-06-25 04:01PM	Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency (Business Wire) +6.30% +9.23%
Dec-16-24 04:01PM	Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.64%
Dec-11-24 11:55AM	Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers (Insider Monkey)
Nov-26-24 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Nov-18-24 08:00PM	Arcturus Therapeutics to Present at Jefferies London Healthcare Conference (Business Wire) +11.00%
Nov-14-24 01:00AM	Meiji Seika Pharma Announces Investment in ARCALIS, Inc. (Business Wire)
Nov-11-24 04:01PM	Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial (Business Wire)
Nov-08-24 12:15PM	Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
02:29AM	Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ... (GuruFocus.com)
Nov-07-24 05:55PM	Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:48PM	Arcturus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress (Business Wire)
Nov-06-24 07:35AM	Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
04:01PM	Loading…
Oct-31-24 04:01PM	Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 (Business Wire)
Oct-30-24 12:00PM	Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Oct-23-24 04:00AM	A slow start for self-amplifying mRNA vaccines (Pharmaceutical Technology)
Sep-30-24 11:12AM	Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses (Benzinga) +5.36%
08:00AM	Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination (PR Newswire)
Sep-13-24 08:15AM	Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma (PR Newswire)
Sep-08-24 04:51PM	Arcturus Therapeutics Holdings Inc. (ARCT): Among the Worst ARK Stocks According to Short Sellers (Insider Monkey)
11:49AM	10 Worst ARK Stocks To Buy According To Short Sellers (Insider Monkey)
Sep-03-24 08:30AM	Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis (Business Wire) -8.10%
Sep-02-24 09:55AM	Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect? (Zacks)
Aug-27-24 05:00PM	Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences (Business Wire)
Aug-23-24 12:00PM	What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock (Zacks)
Aug-05-24 08:59PM	ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:10PM	Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Arcturus Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress (Business Wire)
Aug-01-24 04:01PM	Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference (Business Wire) -8.01%
Jul-18-24 07:30PM	Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024 (Business Wire)
Jul-01-24 04:01PM	Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs (Business Wire) -9.21%
Jun-20-24 08:00AM	Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors (Business Wire)
Jun-15-24 02:49AM	Insider Sale: CFO Andy Sassine Sells 50,000 Shares of Arcturus Therapeutics Holdings Inc (ARCT) (GuruFocus.com)
Jun-07-24 10:30AM	Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference (Business Wire) -25.31%
Jun-04-24 07:00PM	Insider Sale: Chief Scientific Officer & COO Pad Chivukula Sells 26,000 Shares of Arcturus ... (GuruFocus.com) +7.17%
May-28-24 06:30AM	Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program (Business Wire) +26.31%
May-22-24 07:00AM	Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines (GlobeNewswire) +8.48%
May-20-24 08:30AM	Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine (PR Newswire)
May-15-24 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences (Business Wire) +5.12%
May-09-24 11:13AM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:48AM	Arcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: ... (GuruFocus.com)
May-08-24 09:58PM	ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:43PM	Arcturus Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress (Business Wire)
May-01-24 10:01AM	Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for (Zacks) +9.15%
Apr-25-24 04:01PM	Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 (Business Wire)
Mar-28-24 01:34AM	Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares (GuruFocus.com)
Mar-22-24 01:26AM	Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ... (GuruFocus.com)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 12:10PM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:54AM	Q4 2023 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 10:42PM	Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments (GuruFocus.com)
05:10PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:21PM	Arcturus Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress (Business Wire)
Mar-04-24 01:23PM	Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why (Zacks) -5.24%
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace) +9.41%
09:00AM	Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference (Business Wire)
Feb-22-24 08:30AM	Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis (Business Wire) +6.12%
Feb-21-24 01:04PM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024 (InvestorPlace)
Feb-20-24 04:39PM	3 Tech Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
09:00AM	Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024 (Business Wire)
Feb-05-24 08:30AM	New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster (PR Newswire)
Jan-23-24 04:16AM	18 High Growth Low PE Stocks (Insider Monkey)
Jan-05-24 01:17PM	PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems (PR Newswire)
Dec-21-23 08:00AM	CSL and Arcturus Therapeutics ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster (Business Wire)
Dec-17-23 12:03PM	7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar (InvestorPlace)
Dec-13-23 10:39PM	3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024 (InvestorPlace) +11.18% +8.05%
Dec-08-23 10:13AM	12 Best Healthcare Stocks For the Long-Term (Insider Monkey)
Dec-04-23 08:30AM	Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-28-23 08:05AM	Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults (PR Newswire)
07:56AM	Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up (Zacks)
Nov-27-23 08:30AM	Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis (Business Wire) +7.90%
Nov-15-23 01:26PM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2023 Earnings Call Transcript (Insider Monkey) +16.08%
11:30AM	Q3 2023 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 05:19PM	Arcturus Therapeutics Holdings Inc (ARCT) Reports Significant Revenue Growth in Q3 2023 (GuruFocus.com) +9.54%
04:13PM	Arcturus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress (Business Wire)
10:56AM	The 3 Most Undervalued Biotech Stocks to Buy: November 2023 (InvestorPlace)
Oct-25-23 04:01PM	Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023 (Business Wire)
Oct-23-23 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences (Business Wire)
Oct-04-23 11:01PM	Insider Sell: Pad Chivukula Sells 5,000 Shares of Arcturus Therapeutics Holdings Inc (GuruFocus.com)

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chivukula Pad	Chief Scientific Officer & COO	Oct 15 '24	Sale	20.76	12,000	249,121	435,334	Oct 16 09:05 PM
Chivukula Pad	Officer	Oct 15 '24	Proposed Sale	20.76	12,000	249,121		Oct 15 04:29 PM
Marantz Jing L.	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	3,131	Jun 18 09:01 PM
HOLMES EDWARD W	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	3,131	Jun 18 09:01 PM
Markels John	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	3,131	Jun 18 09:00 PM
Marquet Magda	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	3,131	Jun 18 09:00 PM
BARLOW JAMES F	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	13,131	Jun 18 09:00 PM
FARRELL PETER C	Director	Jun 14 '24	Option Exercise	0.00	3,131	0	55,741	Jun 18 09:00 PM
SASSINE ANDY	Chief Financial Officer	Jun 12 '24	Sale	32.03	50,000	1,601,500	220,526	Jun 14 04:06 PM
Chivukula Pad	Chief Scientific Officer & COO	Jun 05 '24	Sale	45.00	114	5,130	447,334	Jun 07 05:01 PM
Chivukula Pad	Chief Scientific Officer & COO	Jun 03 '24	Sale	40.01	26,000	1,040,234	447,448	Jun 04 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARCT

Arcturus Therapeutics Holdings Inc

Upgrade your FINVIZ experience